AR118099A1 - Compuesto de pirimidinil-3,8-diazabiciclo[3.2.1]octanilmetanona cristalina y uso de este - Google Patents

Compuesto de pirimidinil-3,8-diazabiciclo[3.2.1]octanilmetanona cristalina y uso de este

Info

Publication number
AR118099A1
AR118099A1 ARP200100415A ARP200100415A AR118099A1 AR 118099 A1 AR118099 A1 AR 118099A1 AR P200100415 A ARP200100415 A AR P200100415A AR P200100415 A ARP200100415 A AR P200100415A AR 118099 A1 AR118099 A1 AR 118099A1
Authority
AR
Argentina
Prior art keywords
octanylmethanone
diazabicycle
crystaline
pyrimidinyl
compound
Prior art date
Application number
ARP200100415A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR118099A1 publication Critical patent/AR118099A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
ARP200100415A 2019-02-15 2020-02-14 Compuesto de pirimidinil-3,8-diazabiciclo[3.2.1]octanilmetanona cristalina y uso de este AR118099A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962806180P 2019-02-15 2019-02-15

Publications (1)

Publication Number Publication Date
AR118099A1 true AR118099A1 (es) 2021-09-15

Family

ID=69726639

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100415A AR118099A1 (es) 2019-02-15 2020-02-14 Compuesto de pirimidinil-3,8-diazabiciclo[3.2.1]octanilmetanona cristalina y uso de este

Country Status (15)

Country Link
US (2) US12312358B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924355B1 (cg-RX-API-DMAC7.html)
JP (1) JP7561497B2 (cg-RX-API-DMAC7.html)
KR (2) KR102820235B1 (cg-RX-API-DMAC7.html)
CN (1) CN113646310A (cg-RX-API-DMAC7.html)
AR (1) AR118099A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020222083B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015951A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130034C (cg-RX-API-DMAC7.html)
ES (1) ES3065864T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021009761A (cg-RX-API-DMAC7.html)
SG (1) SG11202108863WA (cg-RX-API-DMAC7.html)
TW (1) TWI820301B (cg-RX-API-DMAC7.html)
WO (1) WO2020165788A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202106815B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102820235B1 (ko) * 2019-02-15 2025-06-16 화이자 인코포레이티드 결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도
US12673955B2 (en) 2020-06-09 2026-07-07 Crystal Pharmatech Co., Ltd. Crystal form of p-toluenesulfonate salt of diazabicyclic compound and preparation method therefor
CN114835717A (zh) * 2021-02-01 2022-08-02 杭州领业医药科技有限公司 Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途
CN113461687B (zh) * 2021-08-10 2022-04-19 四川大学华西医院 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5023556A (en) 1990-02-02 1991-06-11 Conax Florida Corporation Sensor circuit response to different fluid conductivities and having time delay feature
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
NO2721710T3 (cg-RX-API-DMAC7.html) 2014-08-21 2018-03-31
KR20260080448A (ko) * 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
KR102820235B1 (ko) * 2019-02-15 2025-06-16 화이자 인코포레이티드 결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도

Also Published As

Publication number Publication date
TWI820301B (zh) 2023-11-01
CA3130034C (en) 2023-12-19
US20220144846A1 (en) 2022-05-12
ZA202106815B (en) 2026-03-25
JP2020138960A (ja) 2020-09-03
EP3924355B1 (en) 2025-12-31
KR102820235B1 (ko) 2025-06-16
SG11202108863WA (en) 2021-09-29
AU2020222083A1 (en) 2021-09-02
EP3924355A1 (en) 2021-12-22
EP3924355C0 (en) 2025-12-31
JP7561497B2 (ja) 2024-10-04
KR20240116855A (ko) 2024-07-30
ES3065864T3 (en) 2026-05-08
CA3130034A1 (en) 2020-08-20
AU2020222083B2 (en) 2022-11-17
US20250282789A1 (en) 2025-09-11
US12312358B2 (en) 2025-05-27
TW202045511A (zh) 2020-12-16
MX2021009761A (es) 2021-12-15
CN113646310A (zh) 2021-11-12
BR112021015951A2 (pt) 2021-10-05
KR20210114470A (ko) 2021-09-23
WO2020165788A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
PE20211207A1 (es) Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1- (3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso
AR088755A1 (es) Formas solidas de un inhibidor de disociacion transtiretina
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
AR090151A1 (es) Compuestos inhibidores de raf
CR20160102A (es) Formas de dosificación de liberación prolongada para un inhibidor de jak 1
WO2013128028A8 (en) Pyrazolo-triazine derivatives as selective cyclin- dependent kinase inhibitors
CL2011000973A1 (es) Compuestos derivados de pirazolo [1,5-a]pirimidina3-cabroxamida; composicion farmaceutica que los comprende, y uso para tratar o disminuir la gravedad de una enfermedad o condicion que responde a la inhibicion de la actividad de una jak quinasa.
GT201400183A (es) Inhibidores de cinasa de fosfoinositida 3 cristalina
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
ZA202106815B (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
PE20130212A1 (es) Formas polimorficas de st-246 y metodos de preparacion
AR095435A1 (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo
EP4454712A3 (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
WO2016125192A3 (en) Processes for the preparation of dolute-gravir
MY200061A (en) Irak inhibitor and preparation method therefor and use thereof
PH12012501340A1 (en) Composition for improving brain function and method for improving brain function
BR112015022207A8 (pt) forma cristalina do composto i, formas cristalinas de sais do composto i e uso do composto i
MX381037B (es) Formas cristalinas y formas de sal de compuestos de 7h-pirrolo [2,3-d]pirimidina y método de preparación de las mismas.
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
MX2013007006A (es) Acoplamientos eficientes de peptidos y su uso en la sintesis y aislamiento de una sal trisodica de ciclopenta[g]quinazolina.
BR112013002194A2 (pt) uso de 1-[2-(2,4-dimetil-fenilsulfanil)fenil] piperazina e seus sais farmaceuticamente aceitáveis
AR090209A1 (es) Polimorfos de 1-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi)bencil)urea y composiciones farmaceuticas que los comprenden
AR091186A1 (es) Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isonicotinamida
PE20100085A1 (es) Formas solidas de (1r,2s,3r)-1-(2-(isoxazol-3-il)-1h-imidazol-4-il)butano-1,2,3,4-tetraol y metodos de uso